medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2009, Number 3

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2009; 22 (3)

Health care cost and disease burden of asthmatic patients at the National Institute of Respiratory Diseases

Tapia DAM, Casas MGA

Language: Spanish
References: 20
Page: 182-189
PDF size: 0. Kb.


ABSTRACT

Background: The concept of disease burden summarizes mortality and morbidity, quantifying the impact of generated disability, and creating an indicator of healthy life expectancy.
Objective: To determine the extent of disease burden generated by asthma in hospitalized patients at the National Institute of Respiratory Diseases between June 2006 and June 2007.
Methods: Retrospective study in which 41 clinical records were randomly selected in order to obtain clinical data, factors associated to asthma exacerbations and costs. Statistical analysis was simple and bivariate. Exacerbation probability was calculated by the Kaplan-Meier procedure. Indirect financial burden included years of life lost, lived years, and disability-adjusted life years.
Results: Asthma caused 9.7% of total admissions, most of them were women of low socioeconomic status from metropolitan area and surrounding states, with a mean ± standard deviation of 1.98 ± 1.80 visits to the emergency room, and 1.12 ± 0.33 hospitalizations; 9.24 ± 5.62 days of stay, and 12 ± 6.33 disability days, there was a loss of 22.0 years of potential life and 23.49 years lived and adjusted for disability. Environmental exposures were to pollution, asbestos and industrial. Passive smoking affected 80%. Probability of positive hereditary background was 16.20-fold higher in the metropolitan area, p ‹ 0.01; half patients had another exacerbation in 4.5 months; predisposing factors were allergic rhinitis, obesity and lack of treatment adherence.
Conclusions: Asthma generated a high institutional cost, affected low-income population and was associated to controllable factors: smoking, obesity, allergic rhinitis, lack of self-care and treatment adherence.


REFERENCES

  1. Hollinghurst S, Gorst C, Fahey T, Hay AD. Measuring the financial burden of acute cough in pre-school children: a cost of illness study. BMC Fam Pract 2008;9:10.

  2. Poureslami IM, Rootman I, Balka E, Devarakonda R, Hatch J, Fitzgerald JM. A systematic review of asthma and health literacy: a cultural-ethnic perspective in Canada. Med Gen Med 2007;9:40.

  3. Accordini S, Corsico A, Cerveri I, et ál. The socio-economic burden of asthma is substantial in Europe. Allergy 2008; 63:116-124.

  4. Gallardo Martínez G, Arias Cruz A, González Díaz SN, Galindo Rodríguez G. Costs due to asthma medical care in a group of children from northeastern México. Rev Alerg Mex 2007;54:82-85.

  5. Santos LA, Oliveira MA, Faresin SM, Santoro IL, Fernandes AL. Direct costs of asthma in Brazil: a comparison between controlled and uncontrolled asthmatic patients. Braz J Med Biol Res 2007;40:943-948.

  6. Simon AE, Chan KS, Forrest CB. Assessment of children´s health-related quality of life in United States with a multidimensional index. Pediatrics 2008; 121:e118-126.

  7. To T, Dell S, Dick P, Cicutto L. The burden of illness experienced by young children associated with asthma: a population-based cohort study. J Asthma 2008;45:45-49.

  8. Miller EK, Griffin MR, Edwards KM, et ál. Influenza burden for children with asthma. Pediatrics 2008; 121:1-8.

  9. Schneider A, Biessecker K, Quinzler R, et ál. Asthma patients with low perceived burden of illness: a challenge for guideline adherence. J Eval Clin Pract 2007;13:846-852.

  10. Edwards SJ, Gruffydd-Jones K, Ryan DP. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin 2007;23:1809-1820.

  11. Doull I, Price D, Thomas M, et ál. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin 2007;23:1147-1159.

  12. Havelaar A. Methodological choices for calculating the disease burden and cost-of-illness of footborne zoonoses in European countries. Report no.07-002. Med Vet Net 2007:1-16.

  13. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001;16:326-331.

  14. Clasificación Internacional de las Enfermedades (CIE) 10ma.Rev. Vol. 1. OMS-OPS; 1995.p.510.

  15. López-Viña A, Agüero-Balbín R, Aller-Álvarez JL, et ál. Guidelines for the diagnosis and management of difficult-to-control asthma. Arch Bronconeumol 2005; 41:513-523.

  16. H. Cámara de Diputados. Centro de Estudios de las Finanzas Públicas. Fecha de acceso: 20 de agosto, 2008, Accesible en: http//www.cefp.gob.mx

  17. Rodrigo C. Severe acute asthma: its management in emergency visits and intensive care. Med Intensiva 2006;30:460-470.

  18. OMS. GINA 2006. Fecha de acceso: 25 de agosto, 2008. Accesible en: http://www.ginaasthma.org

  19. St-Laurent J, Bergeron C, Pagé N, Couture C, Laviolette M, Boulet LP. Influence of smoking on airway inflammation and remodeling in asthma. Clin Exp Allergy 2008;38:1582-1589.

  20. Yang XO, Chang SH, Park H, et ál. Regulation of inflammatory response by IL-17F. J Exp Med 2008;205: 1063-1075.




2020     |     www.medigraphic.com